- Home
- SST vs NRSN Comparison
SST vs NRSN Comparison
Compare SST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | NRSN |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 14.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SST | NRSN |
|---|---|---|
| Price | $4.68 | $0.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $8.50 |
| AVG Volume (30 Days) | ★ 1.3M | 469.0K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $266,129,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $0.25 |
| 52 Week High | $9.30 | $1.30 |
Technical Indicators
Market Signals| Indicator | SST | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 79.86 | 45.62 |
| Support Level | $4.00 | $0.39 |
| Resistance Level | $4.92 | $0.74 |
| Average True Range (ATR) | 0.50 | 0.06 |
| MACD | 0.32 | 0.01 |
| Stochastic Oscillator | 79.06 | 45.24 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.